Alternatives in the treatment of rheumatoid arthritis: reasons for using abatacept

被引：1

作者：

Castaneda, S. ^{[1
]}

Martinez Calatrava, M. J. ^{[2
]}

Herrero-Beaumont, G. ^{[2
]}

机构：

[1] Univ Autonoma Madrid, Serv Reumatol, IIS Princesa, Hosp La Princesa, Madrid, Spain

[2] Univ Autonoma Madrid, Lab Patol Osteoarticular, Serv Reumatol, IIS Fdn Jimenez Diaz, Madrid, Spain

来源：

REVISTA CLINICA ESPANOLA | 2012年 / 212卷 / 05期

关键词：

Rheumatoid arthritis; Classification criteria; DMARD; Biologics; Abatacept; DOUBLE-BLIND; RHEUMATOLOGY/EUROPEAN LEAGUE; EULAR RECOMMENDATIONS; AMERICAN-COLLEGE; CLASSIFICATION CRITERIA; CONSENSUS STATEMENT; TIGHT CONTROL; MANAGEMENT; METHOTREXATE; DISEASE;

D O I：

10.1016/j.rce.2011.09.008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Rheumatoid arthritis (RA) is an aggressive and progressive disease in which the prognosis has improved dramatically since the arrival of biological therapies at the end of the nineties. Nowadays, the main management strategies focus on early diagnosis and treatment, which is now more feasible due to the development of new classification criteria orientated towards diagnosis and classification of early and undifferentiated disease. The implementation of early, individualized and intensive treatment, with the aim of achieving remission or a low disease activity state, has notably improved the results obtained in a great percentage of patients, especially in those with a poorer prognosis. Abatacept is one of the biotechnological agents that have become part of the first line therapeutic armamentarium for early and aggressive RA. The efficacy and safety profile of this drug are very promising for the treatment of patients with RA. (C) 2011 Elsevier Espana, S.L. All rights reserved.

引用

页码：244 / 254

页数：11

共 50 条

[1] Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases [J].

Aikawa, Nadia Emi ;

de Carvalho, Jozelio Freire ;

Almeida Silva, Clovis Artur ;

Bonfa, Eloisa .

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2010, 38 (2-3) :82-89

[2] 2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative [J].

Aletaha, Daniel ;

Neogi, Tuhina ;

Silman, Alan J. ;

Funovits, Julia ;

Felson, David T. ;

Bingham, Clifton O., III ;

Birnbaum, Neal S. ;

Burmester, Gerd R. ;

Bykerk, Vivian P. ;

Cohen, Marc D. ;

Combe, Bernard ;

Costenbader, Karen H. ;

Dougados, Maxime ;

Emery, Paul ;

Ferraccioli, Gianfranco ;

Hazes, Johanna M. W. ;

Hobbs, Kathryn ;

Huizinga, Tom W. J. ;

Kavanaugh, Arthur ;

Kay, Jonathan ;

Kvien, Tore K. ;

Laing, Timothy ;

Mease, Philip ;

Menard, Henri A. ;

Moreland, Larry W. ;

Naden, Raymond L. ;

Pincus, Theodore ;

Smolen, Josef S. ;

Stanislawska-Biernat, Ewa ;

Symmons, Deborah ;

Tak, Paul P. ;

Upchurch, Katherine S. ;

Vencovsky, Jiri ;

Wolfe, Frederick ;

Hawker, Gillian .

ARTHRITIS AND RHEUMATISM, 2010, 62 (09) :2569-2581

[3] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].

ARNETT, FC ;

EDWORTHY, SM ;

BLOCH, DA ;

MCSHANE, DJ ;

FRIES, JF ;

COOPER, NS ;

HEALEY, LA ;

KAPLAN, SR ;

LIANG, MH ;

LUTHRA, HS ;

MEDSGER, TA ;

MITCHELL, DM ;

NEUSTADT, DH ;

PINALS, RS ;

SCHALLER, JG ;

SHARP, JT ;

WILDER, RL ;

HUNDER, GG .

ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324

[4] Risk of Cardiovascular Mortality in Patients With Rheumatoid Arthritis: A Meta-Analysis of Observational Studies [J].

Avina-Zubieta, J. Antonio ;

Choi, Hyon K. ;

Sadatsafavi, Mohsen ;

Etminan, Mahyar ;

Esdaile, John M. ;

Lacaille, Diane .

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (12) :1690-1697

[5] Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs [J].

Avouac, J. ;

Allanore, Y. .

EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (07) :1121-1128

[6] Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility [J].

Bakker, M. F. ;

Jacobs, J. W. G. ;

Verstappen, S. M. M. ;

Bijlsma, J. W. J. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 :56-60

[7] Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis [J].

Bartok, Beatrix ;

Firestein, Gary S. .

IMMUNOLOGICAL REVIEWS, 2010, 233 :233-255

[8] The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].

Breedveld, FC ;

Weisman, MH ;

Kavanaugh, AF ;

Cohen, SB ;

Pavelka, K ;

van Vollenhoven, R ;

Sharp, J ;

Perez, JL ;

Spencer-Green, GT .

ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37

[9] Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists [J].

Carmona, L ;

Gómez-Reino, JJ ;

Rodríguez-Valverde, V ;

Montero, D ;

Pascual-Gómez, E ;

Mola, EM ;

Carreño, L ;

Figueroa, T .

ARTHRITIS AND RHEUMATISM, 2005, 52 (06) :1766-1772

[10] The prevalence of rheumatoid arthritis in the general population of Spain [J].

Carmona, L ;

Villaverde, V ;

Hernández-García, C ;

Ballina, J ;

Gabriel, R ;

Laffon, A .

RHEUMATOLOGY, 2002, 41 (01) :88-95

← 1 2 3 4 5 →